Connect Biopharma (NASDAQ:CNTB) reported preliminary topline Phase 2 results from the Seabreeze STAT Asthma study showing rademikibart improved lung function as an add-on treatment for acute asthma exacerbations with type 2 inflammation.
Rocket Pharmaceuticals (NASDAQ:RCKT) received alignment from the U.S. Food and Drug Administration on continued enrollment, dosing, and key design elements for its global Phase 2 pivotal trial of RP-A501 in patients with Danon disease.
Pulse Biosciences (NASDAQ:PLSE) completed enrollment in the PRECISE-BTN clinical study evaluating its nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules.
SU Group Holdings (NASDAQ:SUGP) agreed through its wholly owned subsidiary to acquire 100% of KM Safety Solution Company for HK$5.616 million, or approximately US$721,000.
Vera Bradley (NASDAQ:VRA) reported fiscal second-quarter 2027 consolidated net revenue of $71.6 million, up 1.1% year-over-year, and returned to profitability from continuing operations.
BioVie (NASDAQ:BIVI) reported topline Phase 2 ADDRESS-LC trial results for bezisterim in Long COVID, showing statistically significant improvements in pre-specified subgroups with higher baseline fatigue, cognitive impairment, and post-exertional malaise.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, an investigational RNA interference therapy designed to silence PCSK9 and APOC3 genes for patients with mixed hyperlipidemia.
V2X (NYSE:VVX) received a $46 million delivery order under the Enterprise-Wide Agile Acquisition Contract IDIQ to provide carriage equipment production for the U.S. Air Force’s Long Range Standoff cruise missile program.
RTX (NYSE:RTX) announced that its Pratt & Whitney business completed the F135 Engine Core Upgrade Risk Reduction Design Review, advancing the propulsion modernization program for the F-35 aircraft.
51Talk Online Education Group (NYSE:COE) reported second-quarter 2026 net revenue of $32.4 million, up 58.8% year-over-year, while active students with attended lesson consumption increased to about 138,100.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
